摘要
目的:探究钠-葡萄糖协同转运蛋白抑制剂辅助左西孟旦对急性心力衰竭患者心功能及预后的影响。方法:纳入我院2022年1月到2023年12月收治的69例患者,按照简单化随机(随机数字表法)分为常规组(n=34,给予常规抗心衰治疗联合左西孟旦)与SGLT2组(n=35,常规组基础上加用SGLT2治疗)。对比两组患者临床疗效,并于治疗前及治疗6 m后采用心电检测仪监测左室容积指数(Left atrial volume index,LAVI)、左室质量指数(Left ventricular mass index,LVMI),以血流动力分析仪检测中心静脉压(Central venous pressure,CVP)、心排血量(Cardiac output,CO),同时统计药物不良反应及再入院率。结果:SGLT2组总疗效显著高于常规组(P<0.05);治疗6 m,两组患者LAVI、LVMI、CVP均显著下降(P<0.05),且SGLT2组均显著低于常规组(P<0.05);治疗6 m,两组患者CO显著上升(P<0.05),且SGLT2组均显著高于常规组(P<0.05);两组药物不良反应发生率差异无统计学意义(P>0.05);SGLT2组再入院率(0.00%)显著低于常规组(11.76%)(P<0.05)。结论:SGLT2抑制剂辅助左西孟旦可有效治疗AHF,加强患者左心室功能,改善血流动力学,药物不良反应小,安全性高,对预后具有积极影响,值得推广应用。
Objective:To explore the influence of sodium-dependent glucose transporter 2(SGLT2)inhibitor-assisted levosimendan on cardiac function and prognosis in patients with acute heart failure(AHF).Methods:A total of 69 patients in the hospital from January 2022 to December 2023 were included and divided into the conventional group(n=34,conventional anti-heart failure treatment combined with levosimendan)and the SGLT2 group(n=35,SGLT2 inhibitor based on conventional group)according to simple randomization(random number table method).The clinical efficacy was compared.Before and after 6 months of treatment,left atrial volume index(LAVI)and left ventricular mass index(LVMI)were monitored using an electrocardiogram,and central venous pressure(CVP)and cardiac output(CO)were measured using a hemodynamic analyzer.Adverse drug reactions and readmission rates were also statistically analyzed.Results:The overall efficacy of the SGLT2 group was significantly higher than that of the conventional group(P<0.05).After 6 months of treatment,both groups showed significant decreases in LAVI,LVMI,and CVP(P<0.05),and the SGLT2 group was significantly lower than the conventional group(P<0.05).After 6 months of treatment,both groups showed significant increases in CO(P<0.05),and the SGLT2 group was significantly higher than the conventional group(P<0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P>0.05).The readmission rate(0.00%)of the SGLT2 group was significantly lower than that of the conventional group(11.76%)(P<0.05).Conclusion:SGLT2 inhibitors assisted with levosimendan can effectively treat AHF,strengthen left ventricular function,improve hemodynamics,have minimal adverse drug reactions,have high safety,and have a positive impact on prognosis,and are worthy of promotion and application.
作者
陈敏
Chen Min(Department of Cardiology,Ganxian District People’s Hospital,Ganzhou 341100,Jiangxi,China)
